Fanapanel

Fanapanel

Clinical data
ATC code	None
Identifiers
IUPAC name {[7-(4-Morpholinyl)-2,3-dioxo-6-(trifluoromethyl)-3,4-dihydro-1(2H)-quinoxalinyl]methyl}phosphonic acid
CAS Number	161605-73-8
PubChem CID	208953
ChemSpider	181046
UNII	E3AP71EM0O
ChEMBL	ChEMBL19892
CompTox Dashboard (EPA)	DTXSID7046093
Chemical and physical data
Formula	C14H15F3N3O6P
Molar mass	409.258 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1c(c(cc2c1[nH]c(=O)c(=O)n2CP(=O)(O)O)N3CCOCC3)C(F)(F)F
InChI InChI=1S/C14H15F3N3O6P/c15-14(16,17)8-5-9-11(6-10(8)19-1-3-26-4-2-19)20(7-27(23,24)25)13(22)12(21)18-9/h5-6H,1-4,7H2,(H,18,21)(H2,23,24,25) Key:WZMQMKNCWDCCMT-UHFFFAOYSA-N

Fanapanel (INN, code name ZK-200775), also known as MPQX, is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor. ^[1] It was under development by Schering AG for the treatment of cerebral ischemia associated with stroke and trauma, but clinical trials were halted for safety reasons related to possible glial cell toxicity and due to intolerable side effects such as excessive sedation, reduction in consciousness (consisting of stupor and coma), and transient neurological deterioration. ^{[2] [3]} The drug was also observed to produce visual alteration and impairment, including blurred vision, strongly impaired color perception, and reduced visual acuity and dark vision, side effects thought to be caused by blockade of AMPA receptors in the retina. ^[4]

References

1. Turski L, Huth A, Sheardown M, McDonald F, Neuhaus R, Schneider HH, et al. (September 1998). "ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma". Proceedings of the National Academy of Sciences of the United States of America. 95 (18): 10960–10965. Bibcode:1998PNAS...9510960T. doi: 10.1073/pnas.95.18.10960 . PMC   28003 . PMID   9724812.
2. Walters MR, Kaste M, Lees KR, Diener HC, Hommel M, De Keyser J, et al. (2005). "The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebo-controlled safety and tolerability study". Cerebrovascular Diseases. 20 (5): 304–309. doi:10.1159/000087929. PMID   16131799. S2CID   25034903.
3. Elting JW, Sulter GA, Kaste M, Lees KR, Diener HC, Hommel M, et al. (December 2002). "AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels". Stroke. 33 (12): 2813–2818. doi: 10.1161/01.str.0000043823.37955.fb . PMID   12468775.
4. Bergholz R, Staks T, Rüther K (August 2010). "Effects of the AMPA antagonist ZK 200775 on visual function: a randomized controlled trial". PLOS ONE. 5 (8) e12111. Bibcode:2010PLoSO...512111B. doi: 10.1371/journal.pone.0012111 . PMC   2920815 . PMID   20711429.